News | August 14, 2012

Statewide Study Helps Reduce Unnecessary Heart Imaging

Beaumont-led and Blue Cross-sponsored initiative enhances CT heart testing quality and value


August 14, 2012 — A study led by Kavitha Chinnaiyan, M.D., director of advanced cardiac imaging education, Beaumont Health System (Mich.), has shown that inappropriate CCTA (coronary computed tomography [CT] angiography) use can be reduced by 60 percent with educational programs, increased physician collaboration and close monitoring. The research is published in the Aug. 8 online issue of the Journal of the American College of Cardiology (JACC).

The results come from a multicenter, statewide quality improvement initiative called the Advanced Cardiovascular Imaging Consortium (ACIC), sponsored by Blue Cross Blue Shield/Blue Care Network of Michigan. A total of 47 centers in Michigan took part in the ongoing initiative from July 2007 to December 2010.

"We looked at more than 25,000 patients in the ACIC registry, reviewed data on appropriate use, then had a period of intervention with 5,000 referring physicians across the state offering educational programs, close monitoring and feedback to physicians on CT use," said Chinnaiyan, ACIC program director.

Coronary CT angiography is the fastest growing application of CT scanners in the United States. About 500,000 Americans undergo CCTA each year at an average cost of $500 to $1,500. As it is a relatively new imaging methodology, the statewide collaborative was formed in part to assess how providers should best utilize the technology, while at the same time reducing inappropriate use. After the intervention, there was a follow-up period where appropriate use was reviewed again. It was found that appropriate use increased and inappropriate use decreased by 60 percent across all referring physician specialties, including cardiologists, internists and emergency room physicians.

"The study suggests that voluntary, mutually established quality metrics reinforced by education and feedback can result in major changes in inappropriate use," said Chinnaiyan. "This collaborative approach involving physicians, hospitals and payers may be applied beyond CCTA to enhance value in other areas of medicine."

Earlier this year, ACIC-generated research found that CCTA is more effective than cardiac stress testing at identifying heart disease requiring an expensive, invasive heart catheterization procedure. That research, also authored by Chinnaiyan, was published in the Feb. 14 issue of JACC.

For more information: www.beaumont.edu


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now